Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting

GlobeNewswire April 20, 2016

Genmab Updates Financial Guidance for 2016

GlobeNewswire April 20, 2016

Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)

GlobeNewswire April 4, 2016

CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma

GlobeNewswire April 1, 2016

Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma

GlobeNewswire March 30, 2016

Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma

GlobeNewswire March 21, 2016

Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees in Genmab

GlobeNewswire March 17, 2016

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

GlobeNewswire March 10, 2016

Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen

GlobeNewswire March 9, 2016

Genmab Announces European Regulatory Submission for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

GlobeNewswire March 9, 2016

Genmab Provides Update on Ofatumumab Development in Autoimmune Indications

GlobeNewswire March 8, 2016

Genmab 2015 Annual Report

Press Releases February 17, 2016

Major Shareholder Announcement

GlobeNewswire February 4, 2016

Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL

GlobeNewswire January 19, 2016

Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen

GlobeNewswire December 21, 2015

Genmab Achieves $3 Million Milestone for Progress in DuoBody Platform Collaboration with Janssen

GlobeNewswire December 18, 2015

Genmab Achieves USD 5 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire December 9, 2015

Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned Interim Analysis

GlobeNewswire November 23, 2015

Genmab Achieves USD 45 Million Milestone in DARZALEX(TM) (daratumumab) Collaboration With Janssen

GlobeNewswire November 19, 2015

Major Shareholder Announcement

GlobeNewswire November 17, 2015